Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.

The Journal of clinical investigation - 2 Oct 2023

Valero Cristina, Golkaram Mahdi, Vos Joris L, Xu Bin, Fitzgerald Conall, Lee Mark, Kaplan Shannon, Han Catherine Y, Pei Xin, Sarkar Reith, Boe Lillian A, Pandey Abhinav, Koh Elizabeth S, Zuur Charlotte L, Solit David B, Pawlowski Traci, Liu Li, Ho Alan L, Chowell Diego, Riaz Nadeem, Chan Timothy A, Morris Luc Gt

Abstract excerpt

BACKGROUNDRecurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is generally an incurable disease, with patients experiencing median survival of under 10 months and significant morbidity. While immune checkpoint blockade (ICB) drugs are effective in approximately 20% of patients, the remaining experience limited clinical benefit and are exposed to potential adverse effects and financial...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Genomics
Head and Neck Neoplasms
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 37561583
DOI: 10.1172/JCI169823
PMCID: PMC10541199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.PMID 37561583Read ↗

Integrative immune subtyping of HNSCC reveals clinically relevant phenotypes and treatment-associated transitionsSemantic proximity Read ↗

Multimodal genomic markers predict immunotherapy response in the head and neck squamous cell carcinomaSemantic proximity Read ↗

Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic VulnerabilitiesSemantic proximity Read ↗

Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancerSemantic proximity Read ↗

Integrating Immune Multi-Omics and Machine Learning to Improve Prognosis, Immune Landscape, and Sensitivity to First- and Second-Line Treatments for Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Identification of Immune-related lncRNA Panel for Predicting Immune Checkpoint Blockade and Prognosis in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Molecular landscape of head and neck cancer and implications for therapySemantic proximity Read ↗

Tumor Subtype Classification Tool for HPV-associated Head and Neck CancersSemantic proximity Read ↗

Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV SubtypesSemantic proximity Read ↗

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.Semantic proximity Read ↗

Novel insights into head and neck cancer using next-generation "omic" technologies.Semantic proximity Read ↗

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.